Glargine ELISA Kit (DEIABL229)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

serum, plasma
Species Reactivity
Intended Use
The Glargine ELISA kit is a solid phase two-site enzyme immunoassay. The assay is designed to measure glargine with high specificity and enhanced sensitivity in serum or plasma.
Store the unopened kit at 2-8°C.
Intra-assay precision (CV%): 3% - 6%. Inter-assay precision (CV%): 9%.
Detection Limit
4.3 μU/mL


Have you cited DEIABL229 in a publication? Let us know and earn a reward for your research.

Related Products

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Nocturnal Hypoglycemia with Insulin Degludec and Glargine U100 in Patients with Type 1 Diabetes Prone to Severe Nocturnal Hypoglycemia (HypoDeg): A CGM Substudy


Authors: Brosen, Julie M.; Agesen, Rikke M.; Alibegovic, Amra Ciric; Andersen, Henrik U.; Gustenhoff, Peter; Hansen, Troels K.; Jensen, Tonny, Sr.; Juhl, Claus B.; Lerche, Susanne; Norgaard, Kirsten; Parving, Hans-Henrik D.; Tarnow, Lise; Thorsteinsson, Birger; Pedersen-Bjergaard, Ulrik

Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index


Authors: Gentilella, Raffaella; Sesti, Giorgio; Vazquez, Luis; Sapin, Helene; Reed, Victoria; Romera, Irene; Pozzilli, Paolo

Aim To assess the relationship between baseline body mass index (BMI) and glycaemic control in dulaglutide-treated patients, a post hoc analysis was conducted on HbA1c and baseline BMI data from eight AWARD studies, with a total of 5770 patients. Materials and methods Changes from baseline in HbA1c data from patients treated with 1.5 mg or 0.75 mg dulaglutide, active comparator or placebo, were analyzed in each study (AWARD-1 to -6, -8 and - 9) at approximately 6 months (26, 24 and 28 weeks, respectively). Within each study, data were analyzed by the following baseline BMI categories: <30, >= 30 to <35, and >= 35 kg/m(2). Results In this post hoc analysis, 1.5 mg or 0.75 mg dulaglutide treatment achieved statistically significant HbA1c reductions from baseline in all BMI categories (least-squares mean change from -0.62 to -1.75%) across the AWARD studies. No statistically significant treatment-by-BMI category interactions were found for reductions in HbA1c. Conclusion This post hoc analysis of eight AWARD studies indicates that baseline BMI does not affect the relative treatment efficacy of dulaglutide as measured by HbA1c change from baseline in any study. Dulaglutide is an effective treatment option for adult patients with type 2 diabetes regardless of their baseline BMI category.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket